Schornagel J H, Simonetti G, Dubbelman R, ten Bokkel Huinink W W, McVie J G
University Hospital, Utrecht, The Netherlands.
Cancer Chemother Pharmacol. 1990;26(3):237-8. doi: 10.1007/BF02897208.
In a phase I study mitozolomide was given on a once daily for 5 days schedule to 18 patients with a variety of malignancies. Non-hematological toxicity was negligible. Significant myelosuppression occurred at a total dose as low as 62.5 mg/m2 per course. In particular, thrombocytopenia, which was unpredictable, precluded dose increments beyond 15 mg/m2 per day (or a total of 75 mg/m2). Antitumor effects were not observed. The 5-day schedule of mitozolomide appears to have no advantage over administration once every 3-4 weeks, and may even be more dangerous than the latter schedule.
在一项I期研究中，对18例患有各种恶性肿瘤的患者按照每日一次、持续5天的给药方案给予米托唑胺。非血液学毒性可忽略不计。在每个疗程总剂量低至62.5mg/m²时出现了显著的骨髓抑制。特别是血小板减少症不可预测，使得每日剂量增量不能超过15mg/m²（或总计75mg/m²）。未观察到抗肿瘤效果。米托唑胺的5天给药方案似乎并不比每3 - 4周给药一次更具优势，甚至可能比后者的给药方案更危险。
